IP Library Granted Patent US 12,133,894
Granted Patent B2
US 12,133,894 · App. 18/390,700 · Granted Nov 5, 2024

Compositions and methods for delivery of RNA

Inventors: Amit Khandhar (Issaquah, WA); Steven Reed (Bellevue, WA); Malcolm Duthie (Sammamish, WA); Jesse Erasmus (Port Orchard, WA); Darrick Carter (Seattle, WA); Bryan J. Berube (Issaquah, WA)
Assignee: HDT Bio Corp.
A61K47/6907A61K9/1075A61K9/127A61K9/5115A61K9/5123A61K31/7105A61K31/711A61K31/713A61K39/215A61K39/39A61K47/02A61K47/44A61K47/6911A61K47/6923A61K49/183A61K49/1833A61P31/14C07K14/165C12N15/86C12N15/88A61K2039/55555A61K47/10A61K47/26A61K47/547B82Y5/00B82Y25/00B82Y30/00B82Y40/00C12N2770/36143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,133,894
App. No.
18/390,700
Granted
Nov 5, 2024
Kind
B2
Abstract

The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Claims (29)

1. A composition, wherein the composition comprises:

DNA molecules, wherein the DNA molecules comprise a sequence encoding an antigen; and

lipid nanoparticles, wherein noncomplexed lipid nanoparticles are characterized as having a z-average diameter particle size measurement of about 20 nm to about 60 nm when measured using dynamic light scattering, and wherein the lipid nanoparticles comprise:

a surface comprising cationic lipids; and

a hydrophobic core, wherein the hydrophobic core comprises liquid oil,

wherein lipids present in the hydrophobic core are in liquid phase at 25 degrees Celsius, and

wherein the DNA molecules are complexed to the cationic lipids to form DNA molecule-lipid nanoparticle complexes.

2. The composition of claim 1 , wherein the antigen in derived from a virus, a bacterium, a protozoa, or a cancer.

3. The composition of claim 2 , wherein the virus is a Human Immunodeficiency virus (HIV), a hepatitis virus, a Coronavirus, a Venezuelan equine encephalitis (VEE) virus, Zika virus.

4. The composition of claim 1 , wherein the composition further comprises a TLR agonist, a RIG-I agonist, an RNA encoding a protein, a protein, a carbohydrate, a saponin, a viral fragment, or a cellular fragment.

5. The composition of claim 1 , wherein the hydrophobic core further comprises a solid inorganic nanoparticle.

6. The composition of claim 5 , wherein the solid inorganic nanoparticle has an average diameter from about 3 nm to about 50 nm.

7. The composition of claim 5 , wherein the solid inorganic nanoparticle is selected from the group consisting of metal salts, metal oxides, metal hydroxides, and metal phosphates.

8. The composition of claim 5 , wherein the solid inorganic nanoparticle comprises iron oxide.

9. The composition of claim 8 , wherein the iron oxide is magnetite (Fe 3 O 4 ), maghemite (y-Fe 2 O 3 ), wüstite (FeO), hematite (a-Fe 2 O 3 ), or any combination thereof.

10. The composition of claim 1 , wherein the liquid oil is a vegetable oil, an animal oil, or a synthetically prepared oil.

11. The composition of claim 1 , wherein the liquid oil is capric/caprylic triglyceride, vitamin E, lauroyl polyoxylglyceride, monoacylglycerol, squalene, or any combination thereof.

12. The composition of claim 1 , wherein the liquid oil is squalene, sunflower oil, soybean oil, olive oil, grapeseed oil, capric/caprylic triglyceride, or any combination thereof.

13. The composition of claim 1 , wherein the cationic lipid is selected from the group consisting of 1,2-dioleoyloxy-3-(trimethylammonium)propane (DOTAP); 3b-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC Cholesterol); dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl-3-trimethylammoniumpropane (DMTAP); dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP); distearoyltrimethylammonium propane (DSTAP); N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC); 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC);

1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA); and 1, r-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl) (2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C 12-200).

14. The composition of claim 1 , wherein the surface further comprises a hydrophobic surfactant and a hydrophilic surfactant.

15. The composition of claim 14 , wherein the hydrophobic surfactant is selected from the group consisting of sorbitan monostearate, sorbitan monooleate, and sorbitan trioleate.

16. The composition of claim 14 , wherein the hydrophilic surfactant comprises polyethylene oxide or polysorbate.

17. The composition of claim 16 , wherein the polysorbate comprises polysorbate 80.

18. The composition of claim 1 , wherein the DNA molecules further comprise a sequence encoding for an RNA polymerase complex region from an RNA virus.

19. The composition of claim 18 , wherein the RNA polymerase complex region comprises sequence from a Venezuelan equine encephalitis virus.

20. The composition of claim 19 , wherein the Venezuelan equine encephalitis virus is strain TC-83.

21. The composition of claim 18 , wherein the RNA polymerase complex region comprises sequence encoding for nsP1-4.

22. The composition of claim 1 , wherein the composition is formulated as a dry powder.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2024
From: KHANDHAR, AMIT; REED, STEVEN; DUTHIE, MALCOLM; ERASMUS, JESSE; CARTER, DARRICK; BERUBE, BRYAN J.
To: HDT BIO CORP.
Reel/Frame 066131/0841 →
Continuity (8)
Continuation 18357280 · Jul 24, 2023
Continuation 17839574 · Jun 14, 2022
Continuation 17702730 · Mar 23, 2022
Continuation 17523457 · Nov 10, 2021
Continuation PCTUS2021019103 · Feb 22, 2021
Provisional Application 62993307 · Mar 23, 2020
Provisional Application 63054754 · Jul 21, 2020
Related Publication 20240115728A1 · Apr 11, 2024